|Videos|July 31, 2023
Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
Author(s)Joshua K. Sabari, MD, Misako Nagasaka, MD
Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5